IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to…
Month: March 2023
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated…
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are…
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ET…
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
– Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway –…
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE…
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
— NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business,…
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early…
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing Disclosure of…
UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)…
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ:…
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
2022 total revenues of $26.5 million FDA approval of NexoBrid® in December 2022; U.S. commercial…
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs…
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET RAMSEY, N.J. and BOCA…
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical…
Bio-Path Holdings Provides Clinical and Operational Update
Company Expects to Achieve Several Near-Term Clinical Milestones HOUSTON, March 16, 2023 (GLOBE NEWSWIRE) —…
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S….
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully integrated…